Angel News

banner

Back to Homepage

6th May 2021

Parkwalk leads $33 million financing for biopharmaceutical firm Mogrify

Mogrify Limited, a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has completed the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round. 

5th May 2021

Botanical Holdings awarded €4.3m grant for Portuguese operation

 

Botanical Holdings, the investment holding company focusing on the legal medicinal cannabis industry, comfirms that its Portuguese subsidiary, CECO Wellness (part of the EuroCan division) will receive grant funding of up to €4.3 million ($5.2 million) from the Portugal 2020 Fund. This fund is a partnership between the Portuguese government and the European Commission.

29th April 2021

University of Birmingham spinout ChromaTwist secures £300k funding

University of Birmingham spinout ChromaTwist Ltd has secured £300k of seed funding to develop a new class of fluorescent materials for use in bio-sensing and bio-imaging tests for diseases such as cancer and diabetes.

27th April 2021

BGF Nottingham exits BioCity

Growth capital investor, BGF has exited its investment in Nottingham-based life sciences incubation business, BioCity.  

BGF backed BioCity in January 2019 with funding facilitating BioCity’s investment into a number of seed-stage life sciences businesses. BGF has also invested alongside BioCity in deals such as its investment into North West-headquartered proteomic-data science and diagnostics company, Kinomica, in November last year.   

27th April 2021

Uni of Sussex and o2h back creation of Stingray Bio

o2h Ventures, a UK based fund manager through investment in its SEIS and EIS human health funds has made an investment into Stingray Bio Ltd, a new spin out from the University of Sussex supported by the Sussex Innovation Centre.

23rd April 2021

Oxitec receives US$6.8m from Wellcome Trust to scale up Aedes aegypti technology

Oxitec Ltd, the leading developer of insect-based biological solutions to control pests that transmit disease, destroy crops, and harm livestock, has received US$6.8 million in funding from the Wellcome Trust, one of the world’s largest charitable foundations, to fund scale-up programs for Oxitec’s just-add-water Friendly™ Aedes aegypti technology.

21st April 2021

Biotech startup Halo Therapeutics develops COVID treatments

A team of top scientists from the University of Bristol have formed a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

Bristol-based Halo Therapeutics is backed by Charles Grimsdale (former Eden Ventures), Keith MacDonald and Mark Farmer (of Eden Ventures) and a group of Angels from the Bristol area.  It was founded by the team of leading scientists who made a recent breakthrough discovery, which was published in Science Magazine. They found that exposing the SARS-CoV-2 (Coronavirus) virus to a free fatty acid called linoleic acid locks the virus’s spike protein into a closed, non-infective form stopping it in its tracks.

20th April 2021

Origin co-leads £2m investment in Somaserve

SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers has completed a highly successful, oversubscribed Series A funding of £2.1m.

The funding round was jointly led by Origin Capital and Meltwind, and had follow on investment from all existing investors including Abcam and o2H Ventures. The success of this funding round is testament to the progress made with collaborators in evaluating PolyNaut® for penetrating the blood-brain barrier (BBB) and the launch by Abcam of PolyNaut®-Dye products.

14th April 2021

Maven Equity Finance leads £2m funding round in chemical technology company

Maven Equity Finance, part of the Northern Powerhouse Investment Fund (NPIF) and managed by Maven Capital Partners, has led a £2 million funding round for LCC (Liverpool Chirochem Limited), an international chemical technology business whose products form the building blocks to the research and development of new drugs. The NPIF - Maven Equity Fund invested £1 million, alongside the £1 million from the Government’s Future Fund.

13th April 2021

Pioneering consumer drug company Maxwellia raises £3.2m from Praetura

Maxwellia, a business that is poised to transform the UK’s self-care market has secured a £3.2m investment in a funding round led by Praetura Ventures.

Maxwellia, which is based at Alderley Park in Cheshire, aims to give people easier and faster access to the treatments they need by converting prescription-only medicines to versions that can be bought in a pharmacy.

13th April 2021

IW Capital leads second round of funding for Flarin

Following the initial investment in 2019, IW Capital has led the second round of funding to support the exciting development of this fast-growing business. Over the past year, Flarin has seen expansion through sales of Flarin Joint and Muscular Pain Relief into mass multiples such as Boots, Superdrug, Sainsbury, Morrisons as well as Amazon, Ocado and other online retailers.

12th April 2021

QVentures invests in Béa Fertility

QVentures has invested in Béa Fertility, bringing at-home fertility treatments to the UK. Healthcare start-up Béa Fertility has raised $1m to bring a pioneering at-home fertility treatment to the UK. QVentures joins the round led by Calm/Storm VC and which includes an innovation grant from the recent Innovate UK SMART competition.

Items of 312NEXT

Back to Homepage